{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:34:50Z","timestamp":1793003690118,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:00:00Z","timestamp":1792972800000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Methods"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ymeth.2026.10.006","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:11:07Z","timestamp":1792739467000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A live-cell medium-throughput assay for quantifying lipid accumulation in hepatocytes"],"prefix":"10.1016","author":[{"given":"Mun C.D.","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Nowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Turpin-Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-2423","authenticated-orcid":false,"given":"Bernard L.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymeth.2026.10.006_b0005","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: How is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0010","first-page":"S41","article-title":"Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"Noureddin","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ymeth.2026.10.006_b0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12933-025-02824-3","article-title":"Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality","volume":"24","author":"Han","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0020","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.3390\/biomedicines13112821","article-title":"(full list in appendix), Prevalence and risk factors of MASLD in prediabetes and type 2 diabetes mellitus in Belgium and the Netherlands","volume":"13","author":"Heyens","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymeth.2026.10.006_b0025","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0030","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/j.jhep.2024.02.001","article-title":"Systemic metabolic abnormalities: Key drivers of complications and mortality in MASLD","volume":"80","author":"Fan","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2025.103965","article-title":"Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality","volume":"35","author":"Kim","year":"2025","journal-title":"Nutrition, Metabolism and Cardiovascular Diseases"},{"key":"10.1016\/j.ymeth.2026.10.006_b0040","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"(full list in appendix), Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1990\u20132017: A systematic analysis for the global burden of disease study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ymeth.2026.10.006_b0045","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ymeth.2026.10.006_b0050","article-title":"(full list in appendix), Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.ymeth.2026.10.006_b0055","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"(full list in appendix), Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0060","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000323","article-title":"(full list in appendix), AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ymeth.2026.10.006_b0065","unstructured":"U.S. Food & Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease, 2024 (accessed 16 Feb 2025)."},{"key":"10.1016\/j.ymeth.2026.10.006_b0070","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"(full list in appendix), Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymeth.2026.10.006_b0075","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"(full list in appendix), Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymeth.2026.10.006_b0080","unstructured":"U.S. Food & Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash, 2025 (accessed 21 Sep 2026)."},{"key":"10.1016\/j.ymeth.2026.10.006_b0085","first-page":"92791","article-title":"Metabolic dysfunction-associated steatotic liver disease heterogeneity: need of subtyping","volume":"15","author":"Habib","year":"2024","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.ymeth.2026.10.006_b0095","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.drudis.2018.10.009","article-title":"The power of combining phenotypic and target-focused drug discovery","volume":"24","author":"Heilker","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymeth.2026.10.006_b0100","article-title":"Advancements in MAFLD modeling with human cell and organoid models","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymeth.2026.10.006_b0105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI198334","article-title":"The pathogenesis of hepatic steatosis in MASLD: A lipid droplet perspective","volume":"135","author":"Krahmer","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ymeth.2026.10.006_b0110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/2472555217741077","article-title":"A cell-based assay to investigate hypolipidemic effects of nonalcoholic fatty liver disease therapeutics","volume":"23","author":"Dave","year":"2018","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ymeth.2026.10.006_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2024.100213","article-title":"A simple, reliable and easily generalizable cell-based assay for screening potential drugs that inhibit lipid accumulation","volume":"8","author":"Yang","year":"2025","journal-title":"Curr. Res. Toxicol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cbi.2009.07.019","article-title":"(full list in appendix), Cytometric analysis for drug-induced steatosis in HepG2 cells","volume":"181","author":"Donato","year":"2009","journal-title":"Chem.-Biol. Interact."},{"key":"10.1016\/j.ymeth.2026.10.006_b0125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/1087057111427586","article-title":"High-content imaging technology for the evaluation of drug-induced steatosis using a multiparametric cell-based assay","volume":"17","author":"Donato","year":"2012","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.ymeth.2026.10.006_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107727","article-title":"full list in appendixCharacterization of an in vitro steatosis model simulating activated de novo lipogenesis in MAFLD patients","volume":"26","author":"Kim","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.ymeth.2026.10.006_b0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10565-020-09544-2","article-title":"(full list in appendix), Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists","volume":"37","author":"Boeckmans","year":"2021","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0140","doi-asserted-by":"crossref","first-page":"15837","DOI":"10.1038\/s41598-023-42785-9","article-title":"Micropatterned primary hepatocyte co-culture (HEPATOPAC) for fatty liver disease modeling and drug screening","volume":"13","author":"Cottier","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymeth.2026.10.006_b0145","doi-asserted-by":"crossref","first-page":"22765","DOI":"10.1038\/s41598-021-01951-7","article-title":"(full list in appendix), A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates","volume":"11","author":"Str\u00f6bel","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymeth.2026.10.006_b0150","article-title":"Resmetirom ameliorates NASH-model mice by suppressing STAT3 and NF-\u03baB signaling pathways in an RGS5-dependent manner","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymeth.2026.10.006_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13061315","article-title":"(full list in appendix), Combination therapy of half-dose resmetirom and metformin attenuates metabolic dysfunction-associated steatohepatitis through improving cholesterol metabolism and inflammation","volume":"13","author":"Liu","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymeth.2026.10.006_b0160","article-title":"DGAT2 stability is increased in response to DGAT1 inhibition in gene edited HepG2 cells","volume":"1866","author":"McFie","year":"2021","journal-title":"Biochim. Biophys. Acta - Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ymeth.2026.10.006_b0165","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/ATVBAHA.114.304584","article-title":"Roles of acyl-CoA:diacylglycerol acyltransferases 1 and 2 in triacylglycerol synthesis and secretion in primary hepatocytes","volume":"35","author":"Li","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0170","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acs.biochem.8b01071","article-title":"Monitoring lipid droplet dynamics in living cells by using fluorescent probes","volume":"58","author":"Tatenaka","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymeth.2026.10.006_b0175","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1039\/D4TB01871K","article-title":"Live cell imaging of lipid droplets: Fluorescent chalcones as probes for lipophagy and lipid\u2013mitochondria interactions","volume":"13","author":"Ghorpade","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ymeth.2026.10.006_b0180","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1039\/D0OB01277G","article-title":"Live-cell imaging of lipid droplets using solvatochromic coumarin derivatives","volume":"18","author":"Jana","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ymeth.2026.10.006_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2024.153829","article-title":"A 3D spheroid model of quadruple cell co-culture with improved liver functions for hepatotoxicity prediction","volume":"505","author":"Sun","year":"2024","journal-title":"Toxicology"},{"key":"10.1016\/j.ymeth.2026.10.006_b0190","article-title":"Use of BODIPY (493\/503) to visualize intramuscular lipid droplets in skeletal muscle","volume":"2011","author":"Spangenburg","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101849","article-title":"Labeling and analyzing lipid droplets in mouse muscle stem cells","volume":"3","author":"Chen","year":"2022","journal-title":"STAR Protoc."},{"key":"10.1016\/j.ymeth.2026.10.006_b0200","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.1912","article-title":"BODIPY 493\/503 staining of neutral lipid droplets for microscopy and quantification by flow cytometry","volume":"6","author":"Qiu","year":"2016","journal-title":"Bio-Protoc."},{"key":"10.1016\/j.ymeth.2026.10.006_b0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cyto.990170207","article-title":"Factors underlying the variability of lipid droplet fluorescence in MA-10 Leydig tumor cells","volume":"17","author":"Gocze","year":"1994","journal-title":"Cytometry"},{"key":"10.1016\/j.ymeth.2026.10.006_b0210","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1021\/acsomega.8b00434","article-title":"(full list in appendix), From live cells to Caenorhabditis elegans: Selective staining and quantification of lipid structures using a fluorescent hybrid benzothiadiazole derivative","volume":"3","author":"Mota","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ymeth.2026.10.006_b0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1194\/jlr.M600155-JLR200","article-title":"Temporal and spatial variations of lipid droplets during adipocyte division and differentiation","volume":"48","author":"Nagayama","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymeth.2026.10.006_b0220","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2133\/dmpk.24.300","article-title":"Albumin as fatty acid transporter","volume":"24","author":"van der Vusse","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ymeth.2026.10.006_b0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12986-020-0434-8","article-title":"(full list in appendix), Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis","volume":"17","author":"Zeng","year":"2020","journal-title":"Nutr. Metab. (Lond)"},{"key":"10.1016\/j.ymeth.2026.10.006_b0230","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/cr.2009.25","article-title":"Repression of PKR mediates palmitate-induced apoptosis in HepG2 cells through regulation of Bcl-2","volume":"19","author":"Yang","year":"2009","journal-title":"Cell Res."},{"key":"10.1016\/j.ymeth.2026.10.006_b0235","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/13880209.2020.1803365","article-title":"(full list in appendix), Cyclocarya paliurus extract attenuates hepatic lipid deposition in HepG2 cells by the lipophagy pathway","volume":"58","author":"Yang","year":"2020","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0240","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12944-019-1118-0","article-title":"(full list in appendix), Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis","volume":"18","author":"Yang","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ymeth.2026.10.006_b0245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2144\/000114285","article-title":"In vitro use of free fatty acids bound to albumin: A comparison of protocols","volume":"58","author":"Oliveira","year":"2015","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymeth.2026.10.006_b0250","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1172\/JCI114301","article-title":"At physiologic albumin\/oleate concentrations oleate uptake by isolated hepatocytes, cardiac myocytes, and adipocytes is a saturable function of the unbound oleate concentration. uptake kinetics are consistent with the conventional theory","volume":"84","author":"Sorrentino","year":"1989","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ymeth.2026.10.006_b0255","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1749-6632.1973.tb20490.x","article-title":"Increasing activity of sulfonamides with displacing agents: A review","volume":"226","author":"Anton","year":"1973","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymeth.2026.10.006_b0260","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.xphs.2021.05.018","article-title":"Impact of changes in free concentrations and drug-protein binding on drug dosing regimens in special populations and disease states","volume":"110","author":"Celestin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ymeth.2026.10.006_b0265","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ymeth.2026.10.006_b0270","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/ol102758z","article-title":"Highly water-soluble neutral BODIPY dyes with controllable fluorescence quantum yields","volume":"13","author":"Zhu","year":"2011","journal-title":"Org. Lett."},{"key":"10.1016\/j.ymeth.2026.10.006_b0275","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jphotochem.2018.10.002","article-title":"Interaction of tetramethyl-substituted BODIPY dye with bovine serum albumin: Spectroscopic study and molecular docking","volume":"368","author":"Ksenofontov","year":"2019","journal-title":"J. Photochem. Photobiol. A: Chem"},{"key":"10.1016\/j.ymeth.2026.10.006_b0280","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1134\/S0006350914010217","article-title":"The interaction of BODIPY with bovine serum albumin and its bilirubin complex","volume":"59","author":"Solomonov","year":"2014","journal-title":"Biophys."},{"key":"10.1016\/j.ymeth.2026.10.006_b0285","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-2275(20)42649-5","article-title":"Binding of long-chain fatty acids to bovine serum albumin","volume":"10","author":"Spector","year":"1969","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymeth.2026.10.006_b0290","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0002-9149(96)00651-0","article-title":"Increases in serum unbound free fatty acid levels following coronary angioplasty","volume":"78","author":"Kleinfeld","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0295","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202000816","article-title":"Punicalagin attenuates palmitate-induced lipid droplet content by simultaneously improving autophagy in hepatocytes","volume":"64","author":"Korovila","year":"2020","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ymeth.2026.10.006_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.775382","article-title":"Differential effects of oleic and palmitic acids on lipid droplet-mitochondria interaction in the hepatic cell line HepG2","volume":"8","author":"Eynaudi","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.ymeth.2026.10.006_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20071629","article-title":"Human multilineage 3D spheroids as a model of liver steatosis and fibrosis","volume":"20","author":"Pingitore","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymeth.2026.10.006_b0310","doi-asserted-by":"crossref","first-page":"24154","DOI":"10.3390\/ijms141224154","article-title":"(full list in appendix), EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD","volume":"14","author":"Vella","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymeth.2026.10.006_b0315","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1039\/C6CP00420B","article-title":"Interaction of BODIPY dyes with bovine serum albumin: A case study on the aggregation of a click-BODIPY dye","volume":"18","author":"Jameson","year":"2016","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ymeth.2026.10.006_b0320","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1002\/sim.5455","article-title":"(full list in appendix), Analysis of high-throughput screening assays using cluster enrichment","volume":"31","author":"Pu","year":"2012","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.ymeth.2026.10.006_b0325","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/dmd.110.035873","article-title":"(full list in appendix), Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes","volume":"39","author":"Guo","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ymeth.2026.10.006_b0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000925","article-title":"Drug-induced regulation of target expression","volume":"6","author":"Iskar","year":"2010","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0335","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2413372121","article-title":"(full list in appendix), Multi-component, time-course screening to develop combination cancer therapies based on synergistic toxicity","volume":"121","author":"Ceribelli","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymeth.2026.10.006_b0340","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s42003-020-01402-5","article-title":"A multi-dimensional, time-lapse, high content screening platform applied to schistosomiasis drug discovery","volume":"3","author":"Chen","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0345","doi-asserted-by":"crossref","DOI":"10.3791\/66072","article-title":"(full list in appendix), Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancer","author":"Colling","year":"2024","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ymeth.2026.10.006_b0350","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0163-7827(03)00051-1","article-title":"Enzymes of triacylglycerol synthesis and their regulation","volume":"43","author":"Coleman","year":"2004","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ymeth.2026.10.006_b0355","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1016\/j.bmcl.2011.08.028","article-title":"(full list in appendix), Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core","volume":"21","author":"Dow","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ymeth.2026.10.006_b0360","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.1021\/acs.jmedchem.5b01006","article-title":"full list in appendix), Discovery and optimization of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2","volume":"58","author":"Futatsugi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymeth.2026.10.006_b0365","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"(full list in appendix), Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0370","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0022-2275(20)39682-6","article-title":"Regulation of hepatic triglyceride lipase by thyroid hormone in HepG2 cells","volume":"34","author":"Kihara","year":"1993","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymeth.2026.10.006_b0375","doi-asserted-by":"crossref","first-page":"13714","DOI":"10.3390\/ijms232213714","article-title":"Cell-specific transport and thyroid hormone receptor isoform selectivity account for hepatocyte-targeted thyromimetic action of MGL-3196","volume":"23","author":"H\u00f6nes","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymeth.2026.10.006_b0380","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1194\/jlr.M093112","article-title":"The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes","volume":"60","author":"Chitraju","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymeth.2026.10.006_b0385","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/j.1742-4658.2012.08684.x","article-title":"Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de\u2003novo synthesized fatty acids in HepG2 cells","volume":"279","author":"Wurie","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.ymeth.2026.10.006_b0390","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.tiv.2007.05.014","article-title":"Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells","volume":"21","author":"Westerink","year":"2007","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ymeth.2026.10.006_b0395","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cmet.2020.06.002","article-title":"(full list in appendix), Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress","volume":"32","author":"Cheng","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymeth.2026.10.006_b0400","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/15279","article-title":"1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis","volume":"5","author":"Hakum\u00e4ki","year":"1999","journal-title":"Nat. Med."},{"issue":"Pt 2","key":"10.1016\/j.ymeth.2026.10.006_b0405","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1042\/bj3360451","article-title":"Cell proliferation, apoptosis and accumulation of lipid droplets in U937-1 cells incubated with eicosapentaenoic acid","volume":"336","author":"Finstad","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymeth.2026.10.006_b0410","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"(full list in appendix), Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymeth.2026.10.006_b0415","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25169074","article-title":"DGAT1 and DGAT2 inhibitors for metabolic dysfunction-associated steatotic liver disease (MASLD) management: Benefits for their single or combined application","volume":"25","author":"Longo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymeth.2026.10.006_b0420","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fphar.2014.00164","article-title":"Composition and applications of focus libraries to phenotypic assays","volume":"5","author":"Wassermann","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0425","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/jcph.2206","article-title":"(full list in appendix), Effect of renal impairment on the pharmacokinetics of firsocostat, an acetyl-coenzyme A carboxylase inhibitor, and cilofexor, a selective nonsteroidal farnesoid X receptor agonist","volume":"63","author":"Weber","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0430","unstructured":"B.-W. Bhumika, Proteomics of lipid accumulation and DGAT inhibition in HepG2 liver carcinoma cells. [Doctoral dissertation, Victoria University of Wellington]"},{"key":"10.1016\/j.ymeth.2026.10.006_b0435","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4093\/dmj.2023.0368","article-title":"DGAT2 plays a crucial role to control ESRRA-PROX1 transcriptional network to maintain hepatic mitochondrial sustainability","volume":"48","author":"Lee","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.ymeth.2026.10.006_b0440","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.cmet.2018.04.004","article-title":"(full list in appendix), DGAT2 inhibition alters aspects of triglyceride metabolism in rodents but not in non-human primates","volume":"27","author":"McLaren","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymeth.2026.10.006_b0445","doi-asserted-by":"crossref","first-page":"E578","DOI":"10.1152\/ajpendo.00365.2018","article-title":"Lipid and glucose metabolism in hepatocyte cell lines and primary mouse hepatocytes: A comprehensive resource for in vitro studies of hepatic metabolism","volume":"316","author":"Nagarajan","year":"2019","journal-title":"Am. J. Physiol. - Endocrinol. Metab."},{"key":"10.1016\/j.ymeth.2026.10.006_b0450","article-title":"The (misleading) role of animal models in drug development","volume":"4\u20132024","author":"Hartung","year":"2024","journal-title":"Front. Drug Discov."},{"key":"10.1016\/j.ymeth.2026.10.006_b0455","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"(full list in appendix), Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ymeth.2026.10.006_b0460","first-page":"924","volume":"10","author":"Wong","year":"2025","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0465","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2022.12.008","article-title":"Inhibition of diacylglycerol acyltransferase 2 versus diacylglycerol acyltransferase 1: Potential therapeutic implications of pharmacology","volume":"45","author":"Amin","year":"2023","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymeth.2026.10.006_b0470","article-title":"Engineering a three-dimensional liver steatosis model","volume":"1871","author":"Johnston","year":"2025","journal-title":"Biochim. Biophys. Acta - Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ymeth.2026.10.006_b0475","doi-asserted-by":"crossref","DOI":"10.1093\/burnst\/tkag015","article-title":"(full list in appendix), Organoid research: New concepts and new technologies","volume":"14","author":"Zhang","year":"2026","journal-title":"Burns Trauma"},{"key":"10.1016\/j.ymeth.2026.10.006_b0480","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s42003-022-03759-1","article-title":"(full list in appendix), Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer","volume":"5","author":"Polanco","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymeth.2026.10.006_b0485","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1021\/jacs.4c16842","article-title":"(full list in appendix), Fluorogenic platform for real-time imaging of subcellular payload release in antibody\u2013drug conjugates","volume":"147","author":"Nadal-Bufi","year":"2025","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.ymeth.2026.10.006_b0490","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/brainsci14080770","article-title":"Real-time analysis of neuronal cell cultures for CNS drug discovery","volume":"14","author":"Akere","year":"2024","journal-title":"Brain Sciences"},{"key":"10.1016\/j.ymeth.2026.10.006_b0495","doi-asserted-by":"crossref","DOI":"10.1002\/0471143030.cb2402s35","article-title":"Fluorescent detection of lipid droplets and associated proteins","volume":"35","author":"Listenberger","year":"2007","journal-title":"Current Protocols in Cell Biology"}],"container-title":["Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046202326002112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046202326002112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:06:57Z","timestamp":1793002017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046202326002112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":99,"alternative-id":["S1046202326002112"],"URL":"https:\/\/doi.org\/10.1016\/j.ymeth.2026.10.006","relation":{},"ISSN":["1046-2023"],"issn-type":[{"value":"1046-2023","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A live-cell medium-throughput assay for quantifying lipid accumulation in hepatocytes","name":"articletitle","label":"Article Title"},{"value":"Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymeth.2026.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}